BERKELEY, Calif. -- XOMA Ltd. , a leader in the discovery and development of therapeutic antibodies, announced that independent researchers today presented results showing that XOMA's antibody to interleukin-1 beta , XOMA 052, was highly effective in reducing production of a protein that supports the proliferation of cancerous human myeloma cells in vitro.